Portfolio Strategy for an Ophthalmic Gene Therapy Pipeline

Challenge

Five retinal indications competed for the same development budget. Scientific leads disagreed on lead indication; BD had three active regional partnership discussions with inconsistent data packages. The board needed a transparent prioritization framework that incorporated regulatory complexity, manufacturing slot constraints, and competitive entry timelines — not only peak sales estimates.

Approach

BEEÑA-E led a structured assessment across scientific differentiation, regulatory path length, CMC complexity, and commercial attractiveness for each indication. We modeled development scenarios with explicit assumptions, stress-tested manufacturing and long-term follow-up burdens, and prepared partnership teasers with aligned data rooms. A governance workshop presented trade-offs to the board with recommended capital allocation and ex-US rights strategy.

Results

• Board-approved portfolio prioritization with documented criteria and reallocation to the lead indication
• Structured outreach for ex-US rights with consistent diligence materials across three partnership tracks
• Deferred lower-priority indications with defined stage-gate criteria for reactivation
• Aligned R&D and BD on a single narrative for investor updates in the following quarter